Cargando…
A UPLC Q-Exactive Orbitrap Mass Spectrometry-Based Metabolomic Study of Serum and Tumor Tissue in Patients with Papillary Thyroid Cancer
Objective: To find the metabolomic characteristics of tumor or para-tumor tissues, and the differences in serums from papillary thyroid cancer (PTC) patients with or without lymph node metastasis. Methods: We collected serums of PTC patients with/without lymph node metastasis (SN1/SN0), tumor and ad...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863332/ https://www.ncbi.nlm.nih.gov/pubmed/36668770 http://dx.doi.org/10.3390/toxics11010044 |
_version_ | 1784875307580260352 |
---|---|
author | Xu, Bo Gao, Wei Xu, Ting Liu, Cuiping Wu, Dan Tang, Wei |
author_facet | Xu, Bo Gao, Wei Xu, Ting Liu, Cuiping Wu, Dan Tang, Wei |
author_sort | Xu, Bo |
collection | PubMed |
description | Objective: To find the metabolomic characteristics of tumor or para-tumor tissues, and the differences in serums from papillary thyroid cancer (PTC) patients with or without lymph node metastasis. Methods: We collected serums of PTC patients with/without lymph node metastasis (SN1/SN0), tumor and adjacent tumor tissues of PTC patients with lymph node metastasis (TN1 and PN1), and without lymph node metastasis (TN0 and PN0). Metabolite detection was performed by ultra-high performance liquid chromatography combined with Q-Exactive orbitrap mass spectrometry (UPLC Q-Exactive). Results: There were 31, 15, differential metabolites in the comparisons of TN1 and PN1, TN0 and PN0, respectively. Seven uniquely increased metabolites and fourteen uniquely decreased metabolites appeared in the lymph node metastasis (TN1 and PN1) group. Meanwhile, the results indicated that four pathways were co-owned pathways in two comparisons (TN1 and PN1, TN0 and PN0), and four unique pathways presented in the lymph node metastasis (TN1 and PN1) group. Conclusions: Common or differential metabolites and metabolic pathways were detected in the lymph node metastasis and non-metastatic group, which might provide novel ways for the diagnosis and treatment of PTC. |
format | Online Article Text |
id | pubmed-9863332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98633322023-01-22 A UPLC Q-Exactive Orbitrap Mass Spectrometry-Based Metabolomic Study of Serum and Tumor Tissue in Patients with Papillary Thyroid Cancer Xu, Bo Gao, Wei Xu, Ting Liu, Cuiping Wu, Dan Tang, Wei Toxics Article Objective: To find the metabolomic characteristics of tumor or para-tumor tissues, and the differences in serums from papillary thyroid cancer (PTC) patients with or without lymph node metastasis. Methods: We collected serums of PTC patients with/without lymph node metastasis (SN1/SN0), tumor and adjacent tumor tissues of PTC patients with lymph node metastasis (TN1 and PN1), and without lymph node metastasis (TN0 and PN0). Metabolite detection was performed by ultra-high performance liquid chromatography combined with Q-Exactive orbitrap mass spectrometry (UPLC Q-Exactive). Results: There were 31, 15, differential metabolites in the comparisons of TN1 and PN1, TN0 and PN0, respectively. Seven uniquely increased metabolites and fourteen uniquely decreased metabolites appeared in the lymph node metastasis (TN1 and PN1) group. Meanwhile, the results indicated that four pathways were co-owned pathways in two comparisons (TN1 and PN1, TN0 and PN0), and four unique pathways presented in the lymph node metastasis (TN1 and PN1) group. Conclusions: Common or differential metabolites and metabolic pathways were detected in the lymph node metastasis and non-metastatic group, which might provide novel ways for the diagnosis and treatment of PTC. MDPI 2022-12-31 /pmc/articles/PMC9863332/ /pubmed/36668770 http://dx.doi.org/10.3390/toxics11010044 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Xu, Bo Gao, Wei Xu, Ting Liu, Cuiping Wu, Dan Tang, Wei A UPLC Q-Exactive Orbitrap Mass Spectrometry-Based Metabolomic Study of Serum and Tumor Tissue in Patients with Papillary Thyroid Cancer |
title | A UPLC Q-Exactive Orbitrap Mass Spectrometry-Based Metabolomic Study of Serum and Tumor Tissue in Patients with Papillary Thyroid Cancer |
title_full | A UPLC Q-Exactive Orbitrap Mass Spectrometry-Based Metabolomic Study of Serum and Tumor Tissue in Patients with Papillary Thyroid Cancer |
title_fullStr | A UPLC Q-Exactive Orbitrap Mass Spectrometry-Based Metabolomic Study of Serum and Tumor Tissue in Patients with Papillary Thyroid Cancer |
title_full_unstemmed | A UPLC Q-Exactive Orbitrap Mass Spectrometry-Based Metabolomic Study of Serum and Tumor Tissue in Patients with Papillary Thyroid Cancer |
title_short | A UPLC Q-Exactive Orbitrap Mass Spectrometry-Based Metabolomic Study of Serum and Tumor Tissue in Patients with Papillary Thyroid Cancer |
title_sort | uplc q-exactive orbitrap mass spectrometry-based metabolomic study of serum and tumor tissue in patients with papillary thyroid cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863332/ https://www.ncbi.nlm.nih.gov/pubmed/36668770 http://dx.doi.org/10.3390/toxics11010044 |
work_keys_str_mv | AT xubo auplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer AT gaowei auplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer AT xuting auplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer AT liucuiping auplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer AT wudan auplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer AT tangwei auplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer AT xubo uplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer AT gaowei uplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer AT xuting uplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer AT liucuiping uplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer AT wudan uplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer AT tangwei uplcqexactiveorbitrapmassspectrometrybasedmetabolomicstudyofserumandtumortissueinpatientswithpapillarythyroidcancer |